Refractory Acute Leukemia clinical trials

Explore recruiting refractory acute leukemia clinical trials.

Recruiting refractory acute leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Acute Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemia

France, Austria, Netherlands, Spain, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients

Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP 5336) in Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Spain, Belgium, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Refractory Acute Leukemia trials by city

Refractory Acute Leukemia in Toronto Refractory Acute Leukemia in Vancouver Refractory Acute Leukemia in Montreal Refractory Acute Leukemia in Calgary Refractory Acute Leukemia in Edmonton Refractory Acute Leukemia in Ottawa Refractory Acute Leukemia in Winnipeg Refractory Acute Leukemia in Quebec City Refractory Acute Leukemia in Hamilton Refractory Acute Leukemia in Kitchener Refractory Acute Leukemia in London Refractory Acute Leukemia in Halifax Refractory Acute Leukemia in New York Refractory Acute Leukemia in Los Angeles Refractory Acute Leukemia in Chicago Refractory Acute Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease